|
SG2013013339A
(en)
*
|
2002-03-13 |
2014-12-30 |
Array Biopharma Inc |
N3 alkylated benzimidazole derivatives as mek inhibitors
|
|
US7235537B2
(en)
*
|
2002-03-13 |
2007-06-26 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivatives as MEK inhibitors
|
|
EP1581527A4
(en)
*
|
2002-12-13 |
2006-11-22 |
Smithkline Beecham Corp |
MIMETICS OF THROMBOPOIETINE
|
|
DE602004020741D1
(de)
*
|
2003-02-26 |
2009-06-04 |
Kowa Co |
Mittel zur behandlung der allergischen kontaktdermatitis
|
|
CA2532067C
(en)
|
2003-07-24 |
2010-12-21 |
Stephen Douglas Barrett |
N-methyle-substituted benzamidazoles
|
|
US7538120B2
(en)
*
|
2003-09-03 |
2009-05-26 |
Array Biopharma Inc. |
Method of treating inflammatory diseases
|
|
US7144907B2
(en)
*
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
PT1673349E
(pt)
|
2003-09-22 |
2010-09-28 |
S Bio Pte Ltd |
Derivados benzimidazole: preparação e aplicações farmacêuticas
|
|
US7517994B2
(en)
|
2003-11-19 |
2009-04-14 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
|
US7732616B2
(en)
*
|
2003-11-19 |
2010-06-08 |
Array Biopharma Inc. |
Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
|
|
CA2546353A1
(en)
|
2003-11-19 |
2005-06-09 |
Array Biopharma Inc. |
Bicyclic inhibitors of mek and methods of use thereof
|
|
CA2546754A1
(en)
*
|
2003-11-21 |
2005-06-09 |
Array Biopharma Inc. |
Akt protein kinase inhibitors
|
|
US20050171182A1
(en)
*
|
2003-12-11 |
2005-08-04 |
Roger Briesewitz |
Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
|
|
MX2007004781A
(es)
|
2004-10-20 |
2007-05-11 |
Applied Research Systems |
Derivados de 3-arilamino piridina.
|
|
JP2008521858A
(ja)
*
|
2004-12-01 |
2008-06-26 |
ラボラトワール セローノ ソシエテ アノニム |
過増殖性疾患を処置するための［１，２，４］トリアゾロ［４，３−ａ］ピリジン誘導体
|
|
US7429667B2
(en)
*
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
|
SG177981A1
(en)
|
2005-05-18 |
2012-02-28 |
Array Biopharma Inc |
4-(phenylamino)-6-oxo-1, 6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
|
|
EP1904061B1
(en)
*
|
2005-06-23 |
2018-12-26 |
Array Biopharma, Inc. |
SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS
|
|
US8039637B2
(en)
*
|
2005-06-23 |
2011-10-18 |
Array Biopharma Inc. |
Process for preparing benzimidazole compounds
|
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
|
AU2012261703B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
HRP20110498T1
(hr)
|
2005-10-07 |
2011-08-31 |
Exelixis |
Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
|
|
AU2013203939B2
(en)
*
|
2005-10-07 |
2015-08-13 |
Exelixis, Inc. |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
|
US7968108B2
(en)
*
|
2005-10-25 |
2011-06-28 |
Metbro Distributing L.P. |
Hydrogen cyanamide pesticide formulations
|
|
US7572460B2
(en)
*
|
2005-10-25 |
2009-08-11 |
Rodrigo Rodriguez-Kabana |
Hydrogen cyanamide pesticide formulations
|
|
TWI405756B
(zh)
*
|
2005-12-21 |
2013-08-21 |
Array Biopharma Inc |
新穎硫酸氫鹽
|
|
EP1966155A1
(en)
*
|
2005-12-21 |
2008-09-10 |
AstraZeneca AB |
Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
|
|
RU2418790C3
(ru)
*
|
2005-12-21 |
2022-03-14 |
Астразенека Аб |
Новая гидросульфатная соль
|
|
CA2534243A1
(fr)
|
2006-01-25 |
2007-07-25 |
Hydro Quebec |
Particules d'oxyde metallique enrobees a faible taux de dissolution, procedes de preparation et utilisation dans les systemes electrochimiques
|
|
GB0601962D0
(en)
|
2006-01-31 |
2006-03-15 |
Ucb Sa |
Therapeutic agents
|
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
|
MX2008013097A
(es)
*
|
2006-04-18 |
2008-10-27 |
Ardea Biosciences Inc |
Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona.
|
|
US8329701B2
(en)
|
2006-07-06 |
2012-12-11 |
Array Biopharma Inc. |
Dihydrofuro pyrimidines as AKT protein kinase inhibitors
|
|
US8063050B2
(en)
|
2006-07-06 |
2011-11-22 |
Array Biopharma Inc. |
Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
ATE532789T1
(de)
|
2006-07-06 |
2011-11-15 |
Array Biopharma Inc |
Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
|
|
EP2049500B1
(en)
*
|
2006-07-06 |
2011-09-07 |
Array Biopharma, Inc. |
Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
|
|
US8492378B2
(en)
|
2006-08-03 |
2013-07-23 |
Takeda Pharmaceutical Company Limited |
GSK-3β inhibitor
|
|
ES2528797T3
(es)
*
|
2006-08-21 |
2015-02-12 |
Genentech, Inc. |
Compuestos de aza-benzotiofenilo y métodos de uso
|
|
ZA200901009B
(en)
*
|
2006-08-21 |
2010-05-26 |
Genentech Inc |
Aza-benzothiophenyl compounds and methods of use
|
|
ES2376771T3
(es)
*
|
2006-08-21 |
2012-03-16 |
Genentech, Inc. |
Compuestos aza-benzofuranilo y métodos de utilización
|
|
WO2008076415A1
(en)
|
2006-12-14 |
2008-06-26 |
Exelixis, Inc. |
Methods of using mek inhibitors
|
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
|
US20100130519A1
(en)
*
|
2007-04-13 |
2010-05-27 |
Stephen Robert Wedge |
Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
|
|
US8509487B2
(en)
*
|
2007-04-19 |
2013-08-13 |
Avago Technologies General Ip (Singapore) Pte. Ltd. |
System and method for optically measuring a parameter of an object
|
|
JP5580735B2
(ja)
|
2007-06-12 |
2014-08-27 |
ジェネンテック， インコーポレイテッド |
Ｎ−置換アザインドール類及び使用方法
|
|
CN103396409B
(zh)
|
2007-07-05 |
2015-03-11 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
US8846683B2
(en)
|
2007-07-05 |
2014-09-30 |
Array Biopharma, Inc. |
Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
|
|
US9409886B2
(en)
|
2007-07-05 |
2016-08-09 |
Array Biopharma Inc. |
Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
|
|
CN101918373B
(zh)
*
|
2007-07-05 |
2013-06-05 |
阵列生物制药公司 |
作为akt蛋白激酶抑制剂的嘧啶基环戊烷
|
|
GB0714384D0
(en)
|
2007-07-23 |
2007-09-05 |
Ucb Pharma Sa |
theraputic agents
|
|
WO2009050506A2
(en)
*
|
2007-10-15 |
2009-04-23 |
Astrazeneca Ab |
Combination 059
|
|
WO2009064675A1
(en)
|
2007-11-12 |
2009-05-22 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
AU2008343065B2
(en)
|
2007-12-19 |
2012-04-05 |
Genentech, Inc. |
5-anilinoimidazopyridines and methods of use
|
|
PT2231662E
(pt)
|
2007-12-19 |
2011-09-12 |
Genentech Inc |
8-anilinoimidazopiridinas e o seu uso como agentes anticancerígenos e/ou anti-inflamatórios
|
|
US8063085B2
(en)
|
2007-12-20 |
2011-11-22 |
Hoffmann-La Roche Inc. |
Substituted hydantoins
|
|
NZ586575A
(en)
|
2007-12-21 |
2012-03-30 |
Genentech Inc |
Azaindolizines and methods of use
|
|
US8853216B2
(en)
*
|
2008-01-09 |
2014-10-07 |
Array Biopharma, Inc. |
Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
|
|
NZ586346A
(en)
*
|
2008-01-09 |
2012-02-24 |
Array Biopharma Inc |
Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
|
|
WO2009093008A1
(en)
|
2008-01-21 |
2009-07-30 |
Ucb Pharma S.A. |
Thieno-pyridine derivatives as mek inhibitors
|
|
SA109300195B1
(ar)
|
2008-03-28 |
2013-04-20 |
Astrazeneca Ab |
تركيبة صيدلانية جديدة مضادة للسرطان
|
|
GB0811304D0
(en)
|
2008-06-19 |
2008-07-30 |
Ucb Pharma Sa |
Therapeutic agents
|
|
EP2293472A1
(en)
|
2008-06-23 |
2011-03-09 |
Panasonic Corporation |
Wireless communication base station apparatus and reference signal allocation method
|
|
MX2010014565A
(es)
*
|
2008-07-01 |
2011-03-04 |
Genentech Inc |
Isoindolona y metodos de uso.
|
|
RU2509078C2
(ru)
|
2008-07-01 |
2014-03-10 |
Дженентек, Инк. |
Бициклические гетероциклы в качестве ингибиторов киназы мек
|
|
UA107183C2
(uk)
|
2008-08-04 |
2014-12-10 |
|
Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
|
|
CN101653607B
(zh)
*
|
2008-08-19 |
2013-02-13 |
鼎泓国际投资（香港）有限公司 |
含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
|
|
EP2358202B1
(en)
*
|
2008-11-03 |
2016-06-15 |
Merck Sharp & Dohme Corp. |
Benzimidazole and aza-benzimidazole carboxamides
|
|
US8993630B2
(en)
|
2008-11-10 |
2015-03-31 |
Bayer Intellectual Property Gmbh |
Substituted sulphonamido phenoxybenzamides
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
|
US20120269803A1
(en)
|
2009-10-21 |
2012-10-25 |
Bayer Intellectual Property Gmbh |
Substituted benzosulphonamides
|
|
US20120263714A1
(en)
|
2009-10-21 |
2012-10-18 |
Bayer Intellectual Property Gmbh |
Substituted halophenoxybenzamide derivatives
|
|
EP2491015A1
(en)
|
2009-10-21 |
2012-08-29 |
Bayer Pharma Aktiengesellschaft |
Substituted benzosulphonamides
|
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
|
US9205086B2
(en)
|
2010-04-19 |
2015-12-08 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
|
|
WO2011131748A2
(en)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Novel inhibitors
|
|
US20130096149A1
(en)
|
2010-06-25 |
2013-04-18 |
Novartis Ag |
Heteroaryl compounds and compositions as protein kinase inhibitors
|
|
EP2600862B1
(en)
|
2010-08-05 |
2016-04-20 |
Case Western Reserve University |
Inhibitors of erk for developmental disorders of neuronal connectivity
|
|
JP5719028B2
(ja)
|
2010-10-06 |
2015-05-13 |
グラクソスミスクライン エルエルシー |
Ｐｉ３キナーゼ阻害剤としてのベンズイミダゾール誘導体
|
|
CN103282351A
(zh)
|
2010-10-29 |
2013-09-04 |
拜耳知识产权有限责任公司 |
取代的苯氧基吡啶
|
|
CN102020651B
(zh)
|
2010-11-02 |
2012-07-18 |
北京赛林泰医药技术有限公司 |
6-芳基氨基吡啶酮甲酰胺mek抑制剂
|
|
WO2012087965A2
(en)
|
2010-12-22 |
2012-06-28 |
Fate Therapauetics, Inc. |
Cell culture platform for single cell sorting and enhanced reprogramming of ipscs
|
|
DK2655375T3
(en)
|
2010-12-23 |
2015-03-09 |
Sanofi Sa |
PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
|
|
TR201815685T4
(tr)
|
2011-04-01 |
2018-11-21 |
Genentech Inc |
Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
|
|
KR102021157B1
(ko)
|
2011-04-01 |
2019-09-11 |
제넨테크, 인크. |
Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법
|
|
WO2012145503A1
(en)
|
2011-04-21 |
2012-10-26 |
Novartis Ag |
Pharmaceutical combinations
|
|
WO2012162293A1
(en)
*
|
2011-05-23 |
2012-11-29 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitory compounds with mek inhibitors
|
|
ES2597052T3
(es)
|
2011-05-25 |
2017-01-13 |
Université Paris Descartes |
Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
|
|
EP2734205B1
(en)
|
2011-07-21 |
2018-03-21 |
Tolero Pharmaceuticals, Inc. |
Heterocyclic protein kinase inhibitors
|
|
JP6238459B2
(ja)
|
2011-08-01 |
2017-11-29 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
|
|
US10813630B2
(en)
|
2011-08-09 |
2020-10-27 |
Corquest Medical, Inc. |
Closure system for atrial wall
|
|
US10307167B2
(en)
|
2012-12-14 |
2019-06-04 |
Corquest Medical, Inc. |
Assembly and method for left atrial appendage occlusion
|
|
US10314594B2
(en)
|
2012-12-14 |
2019-06-11 |
Corquest Medical, Inc. |
Assembly and method for left atrial appendage occlusion
|
|
CN103764144B
(zh)
|
2011-08-31 |
2016-07-20 |
诺华股份有限公司 |
Pi3k抑制剂与mek抑制剂的协同组合
|
|
JP2014528928A
(ja)
*
|
2011-09-01 |
2014-10-30 |
ノバルティス アーゲー |
ヌーナン症候群の治療のための有機化合物の使用
|
|
EP2570127A1
(en)
|
2011-09-16 |
2013-03-20 |
Sanofi |
Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
|
|
RU2629116C2
(ru)
|
2011-10-14 |
2017-08-24 |
Эррэй Биофарма Инк. |
Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
|
|
AU2012332424A1
(en)
|
2011-11-02 |
2014-06-05 |
Synta Pharmaceuticals Corp. |
Combination therapy of Hsp90 inhibitors with platinum-containing agents
|
|
EP2773345A1
(en)
|
2011-11-02 |
2014-09-10 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
|
|
WO2013074594A1
(en)
|
2011-11-14 |
2013-05-23 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with braf inhibitors
|
|
JP6180425B2
(ja)
|
2011-11-23 |
2017-08-23 |
メディミューン，エルエルシー |
Ｈｅｒ３に特異的な結合分子及びそれらの使用
|
|
WO2013082511A1
(en)
|
2011-12-02 |
2013-06-06 |
Genentech, Inc. |
Methods for overcoming tumor resistance to vegf antagonists
|
|
CA2860676A1
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
|
WO2013109142A1
(en)
|
2012-01-16 |
2013-07-25 |
Stichting Het Nederlands Kanker Instituut |
Combined pdk and mapk/erk pathway inhibition in neoplasia
|
|
CN103204827B
(zh)
|
2012-01-17 |
2014-12-03 |
上海科州药物研发有限公司 |
作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
|
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
|
KR102088469B1
(ko)
*
|
2012-03-20 |
2020-03-17 |
노파르티스 아게 |
Mek 억제제 및 igf1r 억제제의 병용 요법
|
|
CN104350415B
(zh)
|
2012-04-09 |
2018-01-16 |
思维奇材料公司 |
转换材料，及其组合物和制造方法
|
|
WO2013177676A1
(en)
|
2012-05-29 |
2013-12-05 |
Switch Materials Inc. |
Optical filter comprising a variable transmittance layer
|
|
AU2013269809B2
(en)
|
2012-05-31 |
2017-12-21 |
Bayer Pharma Aktiengesellschaft |
Biomarkers for determining effective response of treatments of Hepatocellular carcinoma (HCC) patients
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
DK2884979T3
(da)
|
2012-08-17 |
2019-09-02 |
Hoffmann La Roche |
Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
|
|
RS55764B1
(sr)
|
2012-10-02 |
2017-07-31 |
Gilead Sciences |
Inhibitori histonskih demetilaza
|
|
MA38085B1
(fr)
|
2012-10-12 |
2018-11-30 |
Exelixis Inc |
Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer
|
|
DK2909181T3
(da)
|
2012-10-16 |
2017-11-20 |
Tolero Pharmaceuticals Inc |
PKM2-modulatorer og fremgangsmåder til anvendelse deraf
|
|
AR099630A1
(es)
|
2012-10-19 |
2016-08-10 |
Novartis Ag |
Preparación de un inhibidor de mek y formulación que lo comprende
|
|
US20140142689A1
(en)
|
2012-11-21 |
2014-05-22 |
Didier De Canniere |
Device and method of treating heart valve malfunction
|
|
BR112015012497B1
(pt)
*
|
2012-11-29 |
2022-05-17 |
Novartis Ag |
Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial
|
|
US9867825B2
(en)
|
2012-12-20 |
2018-01-16 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
|
EP2752191A1
(en)
|
2013-01-07 |
2014-07-09 |
Sanofi |
Compositions and methods using hdm2 antagonist and mek inhibitor
|
|
CN105229144A
(zh)
|
2013-02-22 |
2016-01-06 |
细胞动力学国际有限公司 |
通过组合的遗传工程和化学工程经由正向编程产生肝细胞
|
|
ES2703208T3
(es)
|
2013-02-27 |
2019-03-07 |
Daiichi Sankyo Co Ltd |
Método de predicción de la sensibilidad a un compuesto que inhibe la vía de transducción de señales de MAPK
|
|
CA2901022C
(en)
|
2013-02-27 |
2021-05-04 |
Epitherapeutics Aps |
Substituted pyridine compounds as inhibitors of histone demethylases
|
|
MX394360B
(es)
|
2013-03-14 |
2025-03-24 |
Sumitomo Pharma Oncology Inc |
Inhibidores de jak2 y alk2 y metodos para su uso.
|
|
UA118846C2
(uk)
*
|
2013-03-21 |
2019-03-25 |
Новартіс Аг |
Комбінована терапія
|
|
AR097617A1
(es)
|
2013-09-13 |
2016-04-06 |
Actelion Pharmaceuticals Ltd |
Derivados antibacterianos del 2h-indazol
|
|
EP3046557A1
(en)
|
2013-09-20 |
2016-07-27 |
Stichting Het Nederlands Kanker Instituut |
Rock in combination with mapk-pathway
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
US9566443B2
(en)
|
2013-11-26 |
2017-02-14 |
Corquest Medical, Inc. |
System for treating heart valve malfunction including mitral regurgitation
|
|
AU2014368619B2
(en)
|
2013-12-19 |
2018-11-22 |
Idorsia Pharmaceuticals Ltd |
Antibacterial 1H-indazole and 1H-indole derivatives
|
|
CA2935804A1
(en)
|
2014-01-14 |
2015-07-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
|
CN104788365B
(zh)
*
|
2014-01-16 |
2018-08-10 |
上海艾力斯医药科技有限公司 |
异烟酰胺衍生物、其制备方法及应用
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
EP3099717B1
(en)
|
2014-01-31 |
2019-03-27 |
Novartis AG |
Antibody molecules to tim-3 and uses thereof
|
|
SG11201606934SA
(en)
|
2014-03-04 |
2016-09-29 |
Fate Therapeutics Inc |
Improved reprogramming methods and cell culture platforms
|
|
AR099612A1
(es)
|
2014-03-04 |
2016-08-03 |
Actelion Pharmaceuticals Ltd |
Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
|
|
US20150259420A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
EP3126345A1
(en)
|
2014-03-31 |
2017-02-08 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
|
WO2015164228A1
(en)
|
2014-04-21 |
2015-10-29 |
Cellular Dynamics International, Inc. |
Hepatocyte production via forward programming by combined genetic and chemical engineering
|
|
ES2687040T3
(es)
|
2014-05-16 |
2018-10-23 |
Idorsia Pharmaceuticals Ltd |
Derivados antibacterianos de quinazolin4(3H)ona
|
|
US10023879B2
(en)
|
2014-06-04 |
2018-07-17 |
Fate Therapeutics, Inc. |
Minimal volume reprogramming of mononuclear cells
|
|
SG11201700074YA
(en)
|
2014-07-15 |
2017-02-27 |
Genentech Inc |
Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
|
SG11201701182VA
(en)
|
2014-08-27 |
2017-03-30 |
Gilead Sciences Inc |
Compounds and methods for inhibiting histone demethylases
|
|
ES2771926T3
(es)
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
|
AU2015327868A1
(en)
|
2014-10-03 |
2017-04-20 |
Novartis Ag |
Combination therapies
|
|
AU2015328411C1
(en)
|
2014-10-06 |
2022-03-03 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對ｐｄ－ｌ１之抗體分子及其用途
|
|
US10842626B2
(en)
|
2014-12-09 |
2020-11-24 |
Didier De Canniere |
Intracardiac device to correct mitral regurgitation
|
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
|
CA2969090C
(en)
|
2014-12-23 |
2023-05-02 |
Novartis Ag |
Triazolopyrimidine compounds and uses thereof
|
|
AU2016211671B2
(en)
|
2015-01-26 |
2022-05-26 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
CN105566225A
(zh)
*
|
2015-02-16 |
2016-05-11 |
苏州晶云药物科技有限公司 |
一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
|
|
JP2016155776A
(ja)
*
|
2015-02-24 |
2016-09-01 |
学校法人兵庫医科大学 |
抗腫瘍効果増強剤および抗腫瘍剤
|
|
HK1248603A1
(zh)
|
2015-03-10 |
2018-10-19 |
Aduro Biotech, Inc. |
用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
|
|
RU2017134379A
(ru)
|
2015-03-25 |
2019-04-03 |
Новартис Аг |
Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
|
|
MA41866A
(fr)
|
2015-03-31 |
2018-02-06 |
Massachusetts Gen Hospital |
Molécules à auto-assemblage pour l'administration ciblée de médicaments
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
|
US20180222982A1
(en)
|
2015-07-29 |
2018-08-09 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
|
AR105646A1
(es)
|
2015-08-11 |
2017-10-25 |
Actelion Pharmaceuticals Ltd |
Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
|
|
US20190008859A1
(en)
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
|
RU2020142739A
(ru)
|
2015-08-28 |
2021-01-15 |
Новартис Аг |
Ингибиторы mdm2 и их комбинации
|
|
AR105889A1
(es)
|
2015-09-03 |
2017-11-22 |
Actelion Pharmaceuticals Ltd |
Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
|
|
SG10202111851YA
(en)
|
2015-10-16 |
2021-12-30 |
Fate Therapeutics Inc |
Platform for the Induction & Maintenance of Ground State Pluripotency
|
|
EP3370768B9
(en)
|
2015-11-03 |
2022-03-16 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
|
CA3003152A1
(en)
|
2015-11-04 |
2017-05-11 |
Fate Therapeutics, Inc. |
Methods and compositions for inducing hematopoietic cell differentiation
|
|
JP6928604B2
(ja)
|
2015-11-04 |
2021-09-01 |
フェイト セラピューティクス，インコーポレイテッド |
万能性細胞のゲノム改変
|
|
WO2017106656A1
(en)
|
2015-12-17 |
2017-06-22 |
Novartis Ag |
Antibody molecules to pd-1 and uses thereof
|
|
CA3010236A1
(en)
|
2016-01-20 |
2017-07-27 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
EP3405568A4
(en)
|
2016-01-20 |
2019-12-04 |
Fate Therapeutics, Inc. |
COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES
|
|
EP3424505A4
(en)
|
2016-03-04 |
2019-10-16 |
Taiho Pharmaceutical Co., Ltd. |
PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
|
MX387795B
(es)
|
2016-06-03 |
2025-03-19 |
Array Biopharma Inc |
Combinaciones farmaceuticas.
|
|
JP7042812B2
(ja)
|
2016-06-20 |
2022-03-28 |
ノバルティス アーゲー |
トリアゾロピリミジン化合物の結晶形態
|
|
WO2017221092A1
(en)
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
WO2017221100A1
(en)
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Imidazopyrimidine compounds useful for the treatment of cancer
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
WO2018065924A1
(en)
*
|
2016-10-04 |
2018-04-12 |
Sun Pharmaceutical Industries Limited |
Intermediates of mitogen-activated protein kinase kinase (map2k or mek) inhibitors and process for their preparation
|
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
|
CN108084078B
(zh)
*
|
2016-11-24 |
2021-07-30 |
中山大学 |
一种治疗银屑病性关节炎疾病的药物阿普斯特的合成方法
|
|
WO2018106595A1
(en)
|
2016-12-05 |
2018-06-14 |
Fate Therapeutics, Inc. |
Compositions and methods for immune cell modulation in adoptive immunotherapies
|
|
EP3372624A1
(en)
|
2017-03-06 |
2018-09-12 |
Henkel AG & Co. KGaA |
One component composition based on compounds with at least two exo-vinylene cyclic carbonate units
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
CN111646946A
(zh)
*
|
2017-11-14 |
2020-09-11 |
深圳市塔吉瑞生物医药有限公司 |
一种取代的苯并咪唑化合物及包含该化合物的组合物
|
|
TW201922291A
(zh)
|
2017-11-16 |
2019-06-16 |
瑞士商諾華公司 |
組合療法
|
|
TW201938165A
(zh)
|
2017-12-18 |
2019-10-01 |
美商輝瑞股份有限公司 |
治療癌症的方法及組合療法
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
SG11202008435SA
(en)
|
2018-03-19 |
2020-10-29 |
Taiho Pharmaceutical Co Ltd |
Pharmaceutical composition including sodium alkyl sulfate
|
|
CN112533602A
(zh)
|
2018-04-05 |
2021-03-19 |
大日本住友制药肿瘤公司 |
Axl激酶抑制剂及其用途
|
|
SG11202011633SA
(en)
|
2018-05-24 |
2020-12-30 |
Janssen Biotech Inc |
Psma binding agents and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
DK4541379T3
(da)
|
2018-07-25 |
2026-02-02 |
Advanced Accelerator Applications S A |
Stabile koncentrerede radionuklidkompleksopløsninger
|
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
|
CN118666832A
(zh)
|
2018-08-17 |
2024-09-20 |
诺华股份有限公司 |
作为smarca2/brm atp酶抑制剂的脲化合物和组合物
|
|
US20210346527A1
(en)
|
2018-09-25 |
2021-11-11 |
Advanced Accelerator Applications (Italy) Srl |
Combination Therapy
|
|
CN113473986B
(zh)
|
2018-11-20 |
2024-10-11 |
恩福莱克逊治疗有限公司 |
用于治疗皮肤疾病萘啶酮苯胺化合物
|
|
AU2019383311B2
(en)
|
2018-11-20 |
2024-12-05 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
|
US12466818B2
(en)
|
2018-11-20 |
2025-11-11 |
Nflection Therapeutics, Inc. |
Thienyl-aniline compounds for treatment of dermal disorders
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
JPWO2020130125A1
(ja)
|
2018-12-21 |
2021-11-04 |
第一三共株式会社 |
抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
|
|
NZ778055A
(en)
|
2019-02-12 |
2025-11-28 |
Sumitomo Pharma America Inc |
Formulations comprising heterocyclic protein kinase inhibitors
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20220143049A1
(en)
|
2019-03-21 |
2022-05-12 |
Onxeo |
A dbait molecule in combination with kinase inhibitor for the treatment of cancer
|
|
CA3133460A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
|
WO2020212832A1
(en)
*
|
2019-04-16 |
2020-10-22 |
Alembic Pharmaceuticals Limited |
Process of preparation of benzimidazole compounds
|
|
BR112021020532A2
(pt)
|
2019-04-19 |
2022-03-15 |
Janssen Biotech Inc |
Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
|
|
TWI817018B
(zh)
|
2019-06-28 |
2023-10-01 |
美商艾瑞生藥股份有限公司 |
用於治療ｂｒａｆ相關的疾病和失調症之化合物
|
|
JP2022539208A
(ja)
|
2019-07-03 |
2022-09-07 |
スミトモ ファーマ オンコロジー， インコーポレイテッド |
チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用
|
|
DK4034535T3
(da)
|
2019-09-26 |
2026-04-07 |
Novartis Ag |
Aza-quinolinforbindelser og anvendelser deraf
|
|
EP4054579A1
(en)
|
2019-11-08 |
2022-09-14 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
|
|
WO2021116901A1
(en)
*
|
2019-12-09 |
2021-06-17 |
Biocon Limited |
Forms of binimetinib and process for preparation thereof
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
WO2021185291A1
(zh)
*
|
2020-03-17 |
2021-09-23 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
JP7805285B2
(ja)
|
2020-04-10 |
2026-01-23 |
大鵬薬品工業株式会社 |
３，５－二置換ベンゼンアルキニル化合物とｍｅｋ阻害剤とを用いた癌治療法
|
|
WO2021250521A1
(en)
|
2020-06-09 |
2021-12-16 |
Array Biopharma Inc. |
4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
|
AU2021358394A1
(en)
|
2020-10-05 |
2023-04-13 |
Pierre Fabre Medicament |
Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
CN112679438A
(zh)
*
|
2020-12-31 |
2021-04-20 |
武汉九州钰民医药科技有限公司 |
制备司美替尼的方法
|
|
CN112759552A
(zh)
*
|
2020-12-31 |
2021-05-07 |
武汉九州钰民医药科技有限公司 |
司美替尼的合成方法
|
|
US12141240B2
(en)
|
2021-01-20 |
2024-11-12 |
Rutgers, The State University Of New Jersey |
Method of calibration using master calibration function
|
|
US20240228480A1
(en)
*
|
2021-01-21 |
2024-07-11 |
Nflection Therapeutics, Inc. |
Processes for preparing pyrrolopyridine-aniline compounds
|
|
US20240059789A1
(en)
|
2021-01-28 |
2024-02-22 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
CN117794929A
(zh)
|
2021-02-02 |
2024-03-29 |
法国施维雅药厂 |
选择性bcl-xl protac化合物及使用方法
|
|
CN117321418A
(zh)
|
2021-03-18 |
2023-12-29 |
诺华股份有限公司 |
癌症生物标志物及其使用方法
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
EP4323356A1
(en)
|
2021-04-13 |
2024-02-21 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
|
US20240207257A1
(en)
*
|
2021-04-15 |
2024-06-27 |
Ideaya Biosciences, Inc. |
Combination therapy comprising a pkc inhibitor and a mek inhibitor
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
EP4346826A4
(en)
|
2021-05-27 |
2025-04-30 |
Mirati Therapeutics, Inc. |
COMBINATION THERAPIES
|
|
BR112023025916A2
(pt)
|
2021-06-09 |
2024-02-27 |
Chugai Pharmaceutical Co Ltd |
Combinação de um inibidor de braf e um inibidor de mek, uso de uma combinação, método para o tratamento ou profilaxia de câncer, composições farmacêuticas e invenção
|
|
CN115490640B
(zh)
*
|
2021-06-17 |
2024-11-26 |
深圳市塔吉瑞生物医药有限公司 |
取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
|
|
KR20240035820A
(ko)
|
2021-07-09 |
2024-03-18 |
플렉시움 인코포레이티드 |
Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
|
|
AU2022383040A1
(en)
|
2021-11-04 |
2024-03-07 |
F. Hoffmann-La Roche Ag |
Novel use of quinazolinone compound for the treatment of cancer
|
|
WO2023084489A1
(en)
|
2021-11-15 |
2023-05-19 |
Pfizer Inc. |
Methods of treating coronavirus disease 2019
|
|
TW202342018A
(zh)
|
2022-03-04 |
2023-11-01 |
美商奇奈特生物製藥公司 |
Mek激酶抑制劑
|
|
US20250339547A1
(en)
|
2022-05-20 |
2025-11-06 |
Novartis Ag |
Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
|
|
IL317102A
(en)
|
2022-05-20 |
2025-01-01 |
Novartis Ag |
EPHA2 BCL-XL inhibitor antibody-drug conjugates and methods of using them
|
|
EP4536226A1
(en)
*
|
2022-06-06 |
2025-04-16 |
Alivus Life Sciences Limited |
Process for preparation of selumetinib and salts thereof
|
|
CN120265291A
(zh)
|
2022-11-18 |
2025-07-04 |
豪夫迈·罗氏有限公司 |
喹唑啉酮化合物的新用途和制剂
|
|
AU2024234194A1
(en)
|
2023-03-10 |
2025-08-07 |
Novartis Ag |
Panras inhibitor antibody-drug conjugates and methods of use thereof
|
|
JPWO2024209717A1
(https=)
|
2023-04-06 |
2024-10-10 |
|
|
|
TWI905527B
(zh)
|
2023-06-01 |
2025-11-21 |
中化合成生技股份有限公司 |
6-(4-溴-2-氯-苯基胺基)-7-氟-3-甲基-3h-苯并咪唑-5-羧酸(2-乙烯基氧基-乙氧基)-醯胺硫酸鹽晶型ａ、ｂ、ｃ、ｄ、ｅ、ｆ及ｇ及其製造方法
|
|
WO2025073765A1
(en)
|
2023-10-03 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Methods of prognosis and treatment of patients suffering from melanoma
|
|
PY24103486A
(es)
|
2023-11-22 |
2025-06-06 |
Servier Lab |
Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
|
|
FR3159741A1
(fr)
|
2024-03-04 |
2025-09-05 |
Pierre Fabre Medicament |
Formulation topique comprenant du binimetinib
|
|
WO2025215536A1
(en)
|
2024-04-10 |
2025-10-16 |
Novartis Ag |
Macrocyclic panras inhibitors for the treatment of cancer
|
|
PL249151B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249149B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249148B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249152B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL249150B1
(pl)
*
|
2025-01-27 |
2026-03-02 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|
|
PL248506B1
(pl)
*
|
2025-01-27 |
2025-12-22 |
Lubelska Polt |
Kompozytowa konstrukcja przekładkowa
|